DMII (Drugs Made In America Acquisition II) Additional Paid-In Capital: $0.00 Mil(As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DMII Drugs Made In America Acquisition II Corp DMII
14 GF Score
Price $10.17
! 2 Warning Signs
View Full Analysis

What is Drugs Made In America Acquisition II Additional Paid-In Capital?

Drugs Made In America Acquisition II DMII 14 Additional Paid-In Capital is $0.00 Mil as of Jun. 2026. GuruFocus rates DMII with a GF Score™ of 14/100. The stock has 2 warning signs investors should review.


Drugs Made In America Acquisition II's annual additional paid-in capital increased from . 20 ($0.00 Mil) to Dec. 2024 ($0.03 Mil) but then declined from Dec. 2024 ($0.03 Mil) to Dec. 2025 ($0.00 Mil).

Drugs Made In America Acquisition II Additional Paid-In Capital Related Terms

Drugs Made In America Acquisition II Additional Paid-In Capital Historical Data

* Premium members only.

The historical data trend for Drugs Made In America Acquisition II's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Drugs Made In America Acquisition II Additional Paid-In Capital Chart

Drugs Made In America Acquisition II Annual Data
Trend Dec24 Dec25
Additional Paid-In Capital
0.03 0.00

Drugs Made In America Acquisition II Quarterly Data
Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Additional Paid-In Capital Get a 7-Day Free Trial 0.03 0.00 0.00 0.00 0.00
DMII
14GF Score
Drugs Made In America Acquisition II Corp DMII
Additional Paid-In Capital is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Drugs Made In America Acquisition II Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)
What does a Additional Paid-In Capital of $0.00 Mil mean?
Drugs Made In America Acquisition II (DMII) has a Additional Paid-In Capital of $0.00 Mil as of Jun. 2026. Additional paid-in capital is the capital a company raises in excess of par value. View historical data on Drugs Made In America Acquisition II and its competitors.
Is Drugs Made In America Acquisition II's Additional Paid-In Capital too high?
Drugs Made In America Acquisition II's current Additional Paid-In Capital is $0.00 Mil. Overall, Drugs Made In America Acquisition II has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Drugs Made In America Acquisition II's Additional Paid-In Capital compare to EVAC and CXII?
Drugs Made In America Acquisition II's Additional Paid-In Capital of $0.00 Mil can be compared against companies in the Diversified Financial Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Additional Paid-In Capital for a Diversified Financial Services company?
A good Additional Paid-In Capital depends on the Diversified Financial Services industry context. However, Additional Paid-In Capital should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Additional Paid-In Capital mean?
A high Additional Paid-In Capital can signal that a stock is expensive relative to its fundamentals. Additional paid-in capital is the capital a company raises in excess of par value. View historical data on Drugs Made In America Acquisition II and its competitors. Drugs Made In America Acquisition II's current Additional Paid-In Capital is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Drugs Made In America Acquisition II stock overvalued right now?
Drugs Made In America Acquisition II (DMII) has a current Additional Paid-In Capital of $0.00 Mil. The current Additional Paid-In Capital is $0.00 Mil. Drugs Made In America Acquisition II's overall GF Score™ is 14/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Additional Paid-In Capital calculated?
Additional Paid-In Capital is calculated from a company's financial statements. For Drugs Made In America Acquisition II (DMII), the current Additional Paid-In Capital is $0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Drugs Made In America Acquisition II Business Description

Address 420 Lexington Avenue, Suite 1402, New York, NY, USA, 10170
Drugs Made In America Acquisition II Corp is a blank check Company.
14GF Score

Get the complete analysis for DMII

Additional Paid-In Capital is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$10.17
Price